FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:647 February 7, 2008 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: Rice and colleagues (Oct. 25 issue)¹ report a severe neonatal presentation of medium-chain acyl–coenzyme A dehydrogenase (MCAD) deficiency and suggest that newborn screening results should be communicated by 72 hours of age. In practice, it is unlikely that newborn screening, however timely, could prevent such events. My colleagues and I documented fatal neonatal presentations in 4 of the 81 patients with MCAD deficiency who were born in Australia between 1994 and 2004.² All died before 72 hours. Five babies in the cohort with other fatty acid–oxidation defects also died, between 22 and 65 hours of age.

Reporting . . . [Full Text of this Article]

Related Letters:

Medium Chain Acyl–Coenzyme A Dehydrogenase Deficiency in a Neonate
Rice G., Brazelton T. III, Maginot K., Srinivasan S., Hollman G., Wolff J. A.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:1781, Oct 25, 2007. Correspondence

This article has been cited by other articles:

• Racke, M. K., Stuve, O. (2008). Natalizumab: increased vigilance is required in treating patients with multiple sclerosis. Therapeutic Advances in Neurological Disorders 1: 155-156  
• Linker, R. A., Kieseier, B. C. (2008). Review: Innovative monoclonal antibody therapies in multiple sclerosis. Therapeutic Advances in Neurological Disorders 1: 33-42 [Abstract]